Presentation is loading. Please wait.

Presentation is loading. Please wait.

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S.

Published byDominick Lucas Modified over 5 years ago

Similar presentations

Presentation on theme: "Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S."— Presentation transcript:

1 Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S. Fenske, Parameswaran N. Hari, Jeanette Carreras, Mei-Jie Zhang, Rammurti T. Kamble, Brian J. Bolwell, Mitchell S. Cairo, Richard E. Champlin, Yi-Bin Chen, César O. Freytes, Robert Peter Gale, Gregory A. Hale, Osman Ilhan, H. Jean Khoury, John Lister, Dipnarine Maharaj, David I. Marks, Reinhold Munker, Andrew L. Pecora, Philip A. Rowlings, Thomas C. Shea, Patrick Stiff, Peter H. Wiernik, Jane N. Winter, J. Douglas Rizzo, Koen van Besien, Hillard M. Lazarus, Julie M. Vose  Biology of Blood and Marrow Transplantation  Volume 15, Issue 11, Pages (November 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence of neutrophil and platelet recovery after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Cumulative incidence of NRM after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Probability of PFS after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Probability of OS after AuHCT for DLBCL analyzed by whether or not rituximab was given before transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 A, Probability of PFS after AuHCT for DLBCL analyzed by whether or not rituximab was given < 6 months or ≥ 6 months before transplantation. B, Probability of OS after AuHCT for DLBCL analyzed by whether rituximab was given < 6 months or ≥ 6 months before transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma  Timothy S."

Similar presentations

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.
Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma  Baldeep Wirk, Timothy S. Fenske,
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
Superior Survival after Autologous vs

Superior Survival after Autologous vs
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis  Sonali.
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma  Robert F. Cornell, Anita D'Souza, Adetola.
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma  Ravi Vij, Shaji Kumar, Mei-Jie Zhang,
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma  Dan T. Vogl, Tao Wang, Waleska S. Pérez,
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First.

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C
Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR  Gregory.

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR  Gregory.

Similar presentations

Ads by Google